US biopharmaceutical company Synaptogenix Inc (Nasdaq: SNPX) announced on Thursday that it has entered into a collaboration agreement with LSU Health New Orleans' Neuroscience Center of Excellence.
The collaboration agreement involves pre-clinical testing of the firm's polyunsaturated fatty acid (PUFA) analogues as a treatment for spinal cord injury (SCI). The studies will compare the analogues with Bryostatin in SCI.
Synaptogenix also revealed that the US Patent and Trademark Office (USPTO) has issued US Patent No. 12,016,837 titled 'Halogenated Esters of Cyclopropanated Unsaturated Fatty Acids for Use in the Treatment of Neurodegenerative Diseases' which covers its family of analogues.
Synaptogenix holds exclusive rights to its PUFA analogues pursuant to a licensing agreement with Cognitive Research Enterprises Inc (CRE), formerly known as the Blanchette Rockefeller Neurosciences Institute.
Akeso presents positive results from registrational Phase III study of ivonescimab
FDA grants Priority Review to Genentech's Enspryng for MOGAD
Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock
BioEdge Research Labs advances transparency in research compound documentation
Insilico Medicine doses first patient in Phase III trial of rentosertib
BridgeBio reports exploratory PROPEL 3 data showing wider clinical trends for oral infigratinib
Tyra Biosciences declares positive Phase 2 results for oral dabogratinib in bladder cancer
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study
Fusion Antibodies secures Canadian patent for OptiMAL
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Orphalan commences Phase 3 study of trientine therapy in Wilson disease